Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

No Hooray for Accuray in Q4

The CyberKnife maker missed Wall Street bottom-line estimates and announced disappointing guidance for fiscal 2020.

5 Top Cancer-Fighting Stocks to Buy Now

Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

Aleafia Health Posts Record High Sales in Q2

The Canadian cannabis producer looks for even stronger growth in the future thanks to its increased production capacity and entrance into new markets.